Medicare AdvantagePrior AuthMedium impact
Daurismo™ (glasdegib) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has implemented a revised prior authorization policy for Daurismo (glasdegib) tablets, requiring approval for newly-diagnosed acute myeloid leukemia patients who are 75+ years old or have comorbidities preventing intensive chemotherapy. The drug must be used in combination with low-dose cytarabine and excludes patients who experienced disease progression while on Daurismo.
Action Required
By January 1, 2026: Billing and clinical teams must implement prior authorization requirements for Daurismo (glasdegib) prescriptions for Humana Medicare Advantage patients. Verify patients meet all three criteria: newly-diagnosed AML, age 75+ or qualifying comorbidities, and combination use with low-dose cytarabine. Update provider workflow to document ECOG performance status, cardiac conditions, and baseline creatinine levels. Claims will be denied without proper prior authorization approval.